Atopic Dermatitis

This study was prompted by recent findings that ultra-low IgE levels (IgE <2.5 kU/L) may be linked with a higher risk of cancers.

Adult patients with moderate-to-severe atopic dermatitis (AD) in the phase 3 BREEZE-AD7 study showed sustained improvement of AD signs and symptoms after 68 weeks with combination treatment of bariticitinib and topical corticosteroids.

Korean patients with allergic diseases, including atopic dermatitis (AD), allergic rhinitis (AR), and asthma, had a higher risk of cataract surgery, and the combination of AD and AR resulted in the highest risk.

Patients exposed to childhood maltreatment were at greater risk for developing atopic disease compared with unexposed counterparts, and risk of atopic dermatitis and allergic rhinoconjunctivitis may have been attentuated by misdiagnosis.

Matthew Zirwas, MD, FAAD, associate professor of dermatology at Ohio University in Athens, Ohio provides updates on treatment options for AD at the 2022 SDPA Fall Conference.

Early life exposure to antibiotics, particularly during weeks 2, 3, and 4 of life, was associated with a decreased risk of atopic dermatitis development.

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on how clinical studies in atopic dermatitis (AD) are increasingly investigating topics that remain unknown for disease management, including primary vs secondary failures and AD pathophysiology across different ethnic groups.

Urban-living Indigenous children and young people in high-income countries reported a higher likelihood of current and severe symptoms of atopic dermatitis (AD) compared with a non-Indigenous population, as well as a higher incidence of bacterial skin infections.

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed why it is important for dermatologists to educate patients on atopic dermatitis (AD) and keep an open mind on variations in disease presentation by skin color.

Pimecrolimus and tacrolimus, 2 topical calcineurin inhibitors for the treatment of atopic dermatitis (AD), were not shown to increase the risk of cancer based on moderate-certainty evidence from a systematic review and meta-analysis.

Real-world patients with atopic dermatitis with dark skin types showed greater mean reduction in disease severity between baseline and 6 months with dupilumab compared with those with light skin types, whereas no differences were observed regarding severity reduction for methotrexate and ciclosporin.

More than 3 billion people worldwide live within highly vulnerable areas with implications for skin health, according to climate change policy makers.

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed how prior authorizations and other insurance requirements are limiting treatment access in atopic dermatitis and how dermatologists can help ameliorate these approval issues.

Dupilumab exhibited similarly significant and sustained improvements in atopic dermatitis (AD) signs, symptoms, and quality of life of adult patients with moderate to severe AD, regardless of age of disease onset, compared with placebo.

A digitally delivered targeted intervention of symptom and trigger education, treatment reminders, lifestyle coaching, and healthy lifestyle support demonstrated significant improvements in treatment adherence and related clinical outcomes among Icelandic patients with atopic dermatitis.

Patients with atopic dermatitis reported that exposure to corticosteroid treatment throughout their lifetime put them at a risk for negative outcomes.

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, discussed recent advancements in immunotherapy for atopic dermatitis and what unmet needs persist to address uptake issues and patient-specific care needs.

Children who lived in apartments or newer buildings were also found to have an increased risk of atopic dermatitis later in life.

Significant alterations were observed in lipid levels and other skin biomarkers for infants who developed atopic dermatitis (AD) vs controls, with phytosphingosine associated with the highest AD prediction accuracy.

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on the importance of shared decision-making in deciding which biologic would best alleviate disease burden in patients with moderate to severe atopic dermatitis.

Early initiation of daily specialized emollient use until 2 months was associated with a reduced incidence of atopic dermatitis development among high-risk infants.

Significantly more patients given ruxolitinib cream vs vehicle demonstrated rapid improvements in itch that were sustained over time.

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, spoke on diagnostic challenges for atopic dermatitis and tips for clinicians in screening for the condition.

Pediatric patients who developed atopic dermatitis (AD) before 2 years of age had an increased risk of neurodevelopmental dysfunction, including gross and fine motor skills, at 6 years old.

Patients with atopic dermatitis (AD) were not found to be at greater risk of venous thromboembolism, regardless of Janus kinase inhibitor use, according to this new meta-analysis.

Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of dermatology at the University of California Davis in Sacramento, explained the utility of type 2 inflammation pathways and the microbiome in understanding the immune dysregulation associated with atopic dermatitis (AD).

Findings of a meta-analysis show that use of dietary elimination had a minimal effect on the severity of atopic dermatitis and may increase the risk of developing immunoglobulin E–mediated food allergy.

Investigator Global Assessment score of very severe atopic dermatitis (AD) was associated with dupilumab discontinuation due to adverse effects, although generally adequate 1-, 2-, and 3-year drug survival rates were also observed.

Most patients with atopic dermatitis had flunctuating levels of depressive symptoms, with having public or no insurance, more severe itch, and skin pain cited as additional predictors of adverse mental health outcomes.

European adult patients with atopic dermatitis most valued therapies that had rapid onset, oral administration, and were able to be paused—even at the expense of reduced efficacy.